Neuroblastoma Market Size & Share, by Treatment Type (Chemotherapy, Immunotherapy); Product Type (Tablets, Vaccines); Distribution Channel (Online, Offline); End-user (Hospitals, Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4902
  • Published Date: May 02, 2023
  • Report Format: PDF, PPT

Companies Dominating the Neuroblastoma Landscape

    • Merck & Co., Inc.,
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Pfizer Inc.
    • United Therapeutics Corporation
    • APEIRON Biologics AG
    • Sanofi S.A.
    • Bayer AG
    • Sun Pharmaceutical Industries Ltd.
    • Y- mabs Therapeutics Inc.
    • Baxter International Inc.
    • Cellectar Biosciences

Browse Key Market Insights with Data Illustration:


In The News

  • An acquisition of Acceleron Pharma Inc., by Merck & Co., has been successfully completed. Merck & Co. sought to acquire Acceleron Pharma Inc. in order to expand its portfolio of biopharmaceuticals and build on its current capabilities in the biopharma space. The acquisition will give Merck & Co. access to Acceleron Pharma Inc.'s pipeline of potential new medicines and technologies, as well as provide the ability to better serve patients around the world.
  • An agreement has been signed by Pfizer Inc. and Seagen Inc. whereby Pfizer intends to acquire Seagen, a global biotechnology company focused on discovering, developing, and commercializing transformative cancer medicines, with a total enterprise value of USD 43 billion for each Seagen share at USD 229 in cash.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 4902
  • Published Date: May 02, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing prevalence of neuroblastoma, the growing awareness about the disease, and the availability of new treatments are the major factors driving the market growth.

The market size of neuroblastoma is anticipated to attain a CAGR of 4% over the forecast period, i.e., 2023-2035.

Lack of awareness about the condition and its symptoms, as well as the side effects associated with the treatments are estimated to be the growth hindering factors for the market expansion.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Merck & Co., Inc., Pfizer Inc., United Therapeutics Corporation, APEIRON Biologics AG, Sanofi S.A., Bayer AG, Sun Pharmaceutical Industries Ltd., Y- mabs Therapeutics Inc., Baxter International Inc., Cellectar Biosciences and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by treatment type, product type, distribution channel, end user and by region.

The chemotherapy segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying